Iambic Moves into New HQ
Press
This is some text inside of a div block.
February 7, 2024
Related announcements
Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins
